vs
Side-by-side financial comparison of Boston Scientific (BSX) and PBF Energy Inc. (PBF). Click either name above to swap in a different company.
PBF Energy Inc. is the larger business by last-quarter revenue ($7.9B vs $5.2B, roughly 1.5× Boston Scientific). Boston Scientific runs the higher net margin — 25.7% vs 2.5%, a 23.2% gap on every dollar of revenue. On growth, PBF Energy Inc. posted the faster year-over-year revenue change (11.9% vs 11.6%). Over the past eight quarters, Boston Scientific's revenue compounded faster (12.4% CAGR vs -4.9%).
Boston Scientific Corporation (BSC) is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
PBF Energy Inc. is a petroleum refining and logistics company that produces and sells transportation fuels, heating oils, lubricants, petrochemical feedstocks, and other petroleum products. The company owns and operated 6 refineries throughout the United States, located in Chalmette, Louisiana; Toledo, Ohio; Paulsboro, New Jersey; the Delaware City Refinery in Delaware City; Torrance, California; Martinez, California. PBF produces a range of products including gasoline, ultra-low-sulfur diese...
BSX vs PBF — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $5.2B | $7.9B |
| Net Profit | $1.3B | $200.2M |
| Gross Margin | 69.5% | 3.5% |
| Operating Margin | — | 3.8% |
| Net Margin | 25.7% | 2.5% |
| Revenue YoY | 11.6% | 11.9% |
| Net Profit YoY | — | 149.4% |
| EPS (diluted) | $0.90 | $1.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $5.2B | $7.9B | ||
| Q4 25 | $5.3B | $7.1B | ||
| Q3 25 | $5.1B | $7.7B | ||
| Q2 25 | $5.1B | $7.5B | ||
| Q1 25 | $4.7B | $7.1B | ||
| Q4 24 | $4.6B | $7.4B | ||
| Q3 24 | $4.2B | $8.4B | ||
| Q2 24 | $4.1B | $8.7B |
| Q1 26 | $1.3B | $200.2M | ||
| Q4 25 | $670.0M | $78.4M | ||
| Q3 25 | $755.0M | $170.1M | ||
| Q2 25 | $795.0M | $-5.2M | ||
| Q1 25 | $672.0M | $-401.8M | ||
| Q4 24 | $563.0M | $-289.3M | ||
| Q3 24 | $468.0M | $-285.9M | ||
| Q2 24 | $322.0M | $-65.2M |
| Q1 26 | 69.5% | 3.5% | ||
| Q4 25 | 69.6% | -1.8% | ||
| Q3 25 | 69.9% | 0.5% | ||
| Q2 25 | 67.7% | -0.8% | ||
| Q1 25 | 68.8% | -5.9% | ||
| Q4 24 | 67.8% | -4.2% | ||
| Q3 24 | 68.8% | -3.4% | ||
| Q2 24 | 69.2% | 0.1% |
| Q1 26 | — | 3.8% | ||
| Q4 25 | 15.6% | 1.8% | ||
| Q3 25 | 20.7% | 3.7% | ||
| Q2 25 | 16.2% | 0.6% | ||
| Q1 25 | 19.8% | -7.2% | ||
| Q4 24 | 14.8% | -5.2% | ||
| Q3 24 | 17.4% | -4.6% | ||
| Q2 24 | 12.6% | -0.9% |
| Q1 26 | 25.7% | 2.5% | ||
| Q4 25 | 12.7% | 1.1% | ||
| Q3 25 | 14.9% | 2.2% | ||
| Q2 25 | 15.7% | -0.1% | ||
| Q1 25 | 14.4% | -5.7% | ||
| Q4 24 | 12.3% | -3.9% | ||
| Q3 24 | 11.1% | -3.4% | ||
| Q2 24 | 7.8% | -0.7% |
| Q1 26 | $0.90 | $1.65 | ||
| Q4 25 | $0.45 | $0.74 | ||
| Q3 25 | $0.51 | $1.45 | ||
| Q2 25 | $0.53 | $-0.05 | ||
| Q1 25 | $0.45 | $-3.53 | ||
| Q4 24 | $0.38 | $-2.41 | ||
| Q3 24 | $0.32 | $-2.49 | ||
| Q2 24 | $0.22 | $-0.56 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $541.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $5.7B |
| Total Assets | — | $14.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $541.8M | ||
| Q4 25 | $2.0B | $527.9M | ||
| Q3 25 | $1.3B | $482.0M | ||
| Q2 25 | $534.0M | $590.7M | ||
| Q1 25 | $725.0M | $468.6M | ||
| Q4 24 | $414.0M | $536.1M | ||
| Q3 24 | $2.5B | $976.7M | ||
| Q2 24 | $2.9B | $1.4B |
| Q1 26 | — | — | ||
| Q4 25 | $11.1B | — | ||
| Q3 25 | $11.1B | — | ||
| Q2 25 | $11.1B | — | ||
| Q1 25 | $10.5B | — | ||
| Q4 24 | $9.0B | — | ||
| Q3 24 | $9.2B | — | ||
| Q2 24 | $9.0B | — |
| Q1 26 | — | $5.7B | ||
| Q4 25 | $24.2B | $5.3B | ||
| Q3 25 | $23.4B | $5.2B | ||
| Q2 25 | $22.4B | $5.1B | ||
| Q1 25 | $22.2B | $5.1B | ||
| Q4 24 | $21.8B | $5.5B | ||
| Q3 24 | $20.7B | $5.9B | ||
| Q2 24 | $20.4B | $6.3B |
| Q1 26 | — | $14.7B | ||
| Q4 25 | $43.7B | $13.0B | ||
| Q3 25 | $42.7B | $13.0B | ||
| Q2 25 | $41.6B | $13.0B | ||
| Q1 25 | $40.1B | $13.0B | ||
| Q4 24 | $39.4B | $12.7B | ||
| Q3 24 | $38.1B | $13.1B | ||
| Q2 24 | $37.1B | $14.1B |
| Q1 26 | — | — | ||
| Q4 25 | 0.46× | — | ||
| Q3 25 | 0.48× | — | ||
| Q2 25 | 0.50× | — | ||
| Q1 25 | 0.47× | — | ||
| Q4 24 | 0.41× | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.44× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BSX
| Cardiovascular | $3.5B | 67% |
| Endoscopy | $736.0M | 14% |
| Urology | $646.0M | 12% |
| Neuromodulation | $318.0M | 6% |
PBF
Segment breakdown not available.
